Epigenetic Silencing of Tumor Suppressor Genes through Promoter Hypermethylation in Oral Squamous Cell Carcinoma: From Molecular Insights to Clinical Applications
Abstract
Oral squamous cell carcinoma (OSCC) continues to be a devastating disease, largely because it is often detected too late and tends to resist conventional therapies. Collectively, promoter hypermethylation of tumor suppressor genes represents an early, reversible, and clinically actionable event in OSCC. Emerging methylation-based biomarkers, particularly salivary gene panels, demonstrate promise for non-invasive early detection and longitudinal monitoring. Furthermore, the reversibility of epigenetic silencing provides a rationale for epigenetic therapies, including DNMT (DNA methyltransferase) inhibitors in combination with immunotherapy. Although most evidence remains exploratory and often extrapolated from broader head and neck cancer cohorts, these molecular insights lay the groundwork for future OSCC-specific diagnostic and therapeutic strategies.
HPV-specific methylation thresholds, such as CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) in HPV-negative cancers—where OSCC-specific thresholds are limited and most data are derived from OPSCC (Oropharyngeal Squamous Cell Carcinoma)—and RASSF1A (Ras Association Domain Family Member 1A) in HPV-positive cancers—primarily based on OPSCC rather than OSCC—improve diagnostic and prognostic precision. New non-invasive approaches for early detection and monitoring, such as saliva-based methylation testing HOXA9/NID2 panels (HomeoboxA9), are also highlighted. This review summarizes new evidence that promoter hypermethylation causes oral squamous cell carcinoma (OSCC) by abnormally silencing tumor suppressor genes. We also examine the molecular basis of this phenomenon, stressing how tobacco exposure and HPV infection affect these cancers' methylation landscapes. We believe that incorporating these epigenetic indicators into clinical practice may improve OSCC management.
Keywords
Full Text:
PDF (Early Version)References
Petti S, Masood M, Scully C. The magnitude of tobacco smoking-betel quid chewing-alcohol drinking interaction effect on oral cancer in South-East Asia. A meta-analysis of observational studies. PLoS One 2013;8:e78999.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
Herman JG, Baylin SB. Gene silencing in cancer by promoter hypermethylation. N Engl J Med 2003;349:2042-54.
Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-López L, Macía-Colón G, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) 2011;4:1061-72.
Liu H, Wang D, Yang Z, Li S, Wu H, Xiang J, et al. Regulation of epigenetic modifications in the head and neck tumour microenvironment. Front Immunol 2022;13:1050982.
Mesgari H, Esmaelian S, Nasiri K, Ghasemzadeh S, Doroudgar P, Payandeh Z. Epigenetic regulation in oral squamous cell carcinoma microenvironment: a comprehensive review. Cancers (Basel) 2023;15:5600.
Ghantous Y, Schussel JL, Brait M. Tobacco and alcohol-induced epigenetic changes in oral carcinoma. Curr Opin Oncol 2018;30:152-8.
Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011;6:692-702.
Asokan GS, Jeelani S, Gnanasundaram N. Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma. J Clin Diagn Res 2014;8:ZC09-12.
Li X, Ren Y, Pei S, Zhao K, Chen G, He Z. Dissecting the role of epigenetic regulation in oral squamous cell carcinoma microenvironment: mechanisms and therapeutics. Front Immunol 2026;17:1758433.
Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15:1319-31.
Lechner M, Fenton TR. The genomics, epigenomics, and transcriptomics of HPV-associated oropharyngeal cancer--understanding the basis of a rapidly evolving disease. Adv Genet 2016;93:1-56.
Huang C, Azizi P, Vazirzadeh M, Aghaei-Zarch SM, Aghaei-Zarch F, Ghanavi J, et al. Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance. J Transl Med 2023;21:621.
Nakagawa T, Matsusaka K, Misawa K, Ota S, Fukuyo M, Rahmutulla B, et al. Stratification of HPV-associated and HPV-negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes. Int J Cancer 2020;146:2460-74.
Melchers LJ, Clausen MJAM, Mastik MF, Slagter-Menkema L, van der Wal JE, Wisman GBA, et al. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma. Epigenetics 2015;10:850-60.
Jayaprakash C, Radhakrishnan R, Ray S, Satyamoorthy K. Promoter methylation of MGMT in oral carcinoma: a population-based study and meta-analysis. Arch Oral Biol 2017;80:197-208.
Chaisaingmongkol J, Popanda O, Warta R, Dyckhoff G, Herpel E, Geiselhart L, et al. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma. Oncogene 2012;31:5108-16.
Rapado-González Ó, López-Cedrún JL, López-López R, Rodríguez-Ces AM, Suárez-Cunqueiro MM. Saliva gene promoter hypermethylation as a biomarker in oral cancer. J Clin Med 2021;10:1931.
Rapado-González Ó, Salta S, López-López R, Henrique R, Suárez-Cunqueiro MM, Jerónimo C. DNA methylation markers for oral cancer detection in non- and minimally invasive samples: a systematic review. Clin Epigenetics 2024;16:105.
Jenkins G, O'Byrne KJ, Panizza B, Richard DJ. Genome stability pathways in head and neck cancers. Int J Genomics 2013;2013:464720.
Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 2011;17:4782-9.
College of American Pathologists. Cancer protocol templates [homepage on the Internet]. Northfield: College of American Pathologists; [cited 2026 Feb 11]. Available from: https://www.cap.org/protocols-and-guidelines/cancer-protocols/current-cancer-protocols/
Shen S, Saito Y, Ren S, Liu C, Guo T, Qualliotine J, et al. Targeting viral DNA and promoter hypermethylation in salivary rinses for recurrent HPV-positive oropharyngeal cancer. Otolaryngol Head Neck Surg 2020;162:512-9.
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther 2019;4:62.
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
Yang SC, Wang WY, Zhou JJ, Wu L, Zhang MJ, Yang QC, et al. Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma. Int Immunopharmacol 2022;111:109113.
Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A 2017;114:E10981-90.
Treppendahl MB, Kristensen LS, Grønbæk K. Predicting response to epigenetic therapy. J Clin Invest 2014;124:47-55.
Viet CT, Yu G, Asam K, Thomas CM, Yoon AJ, Wongworawat YC, et al. The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. Biomark Res 2021;9:42.
Arantes LMRB, de Carvalho AC, Melendez ME, Centrone CC, Góis-Filho JF, Toporcov TN, et al. Validation of methylation markers for diagnosis of oral cavity cancer. Eur J Cancer 2015;51:632-41.
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.